Comparative Pharmacology
Head-to-head clinical analysis: OXYTETRACYCLINE HYDROCHLORIDE versus TETREX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OXYTETRACYCLINE HYDROCHLORIDE versus TETREX.
OXYTETRACYCLINE HYDROCHLORIDE vs TETREX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Oxytetracycline binds reversibly to the 30S ribosomal subunit, inhibiting protein synthesis by blocking the attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
Tetracycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the A site.
250-500 mg orally every 6 hours or 1-2 g/day divided every 12 hours intravenously.
250-500 mg orally every 6 hours or 500 mg to 1 g intravenously every 6-12 hours, not to exceed 4 g/day.
None Documented
None Documented
6-10 hours (prolonged to 48-100 hours in renal impairment; consider dose adjustment in CrCl <50 mL/min)
Terminal elimination half-life: 6-11 hours (mean 8 hours); prolonged in renal impairment (up to 20 hours).
Renal (60-70% unchanged by glomerular filtration); biliary/fecal (20-35%)
Renal: 60% unchanged; biliary/fecal: 40% (mainly as glucuronide conjugates).
Category D/X
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic